Authors reply: Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Authors reply: Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%

Published:2022-01-18 Issue:5 Volume:291 Page:707-708
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Parkin Lianne¹²^ORCID,Williams Sheila¹,Sharples Katrina²³⁴,Barson David¹²,Horsburgh Simon¹²,Jackson Rod⁵,Wu Billy⁶,Dummer Jack²⁴

Affiliation:

1. Department of Preventive and Social Medicine Otago Medical School – Dunedin Campus University of Otago Dunedin New Zealand

2. Pharmacoepidemiology Research Network University of Otago Dunedin New Zealand

3. Department of Mathematics and Statistics University of Otago Dunedin New Zealand

4. Department of Medicine Otago Medical School – Dunedin Campus University of Otago Dunedin New Zealand

5. Department of Epidemiology and Biostatistics Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand

6. Auckland Regional Public Health Service Auckland New Zealand

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.13439

Reference5 articles.

1. Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%: A population‐based nested case–control study

2. Regarding: Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%

3. Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice?

4. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline

5. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3